Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTavistock Regulatory News (TAVI)

Share Price Information for Tavistock (TAVI)

Share Price is delayed by 15 minutes
Get Live Data
3.15    0.00 (0.00%)
Bid:
3.00
Ask:
3.30
Spread: 0.30 (10.00%)
Market Cap: £13.89m
TAVI Live PriceLast checked at - London Stock Exchange

Intraday Tavistock Share Chart

Update re ongoing litigation

2 Oct 2025 07:00

RNS Number : 6833B
Tavistock Investments PLC
02 October 2025
 

Tavistock Investments Plc

("Tavistock" or the "Company")

 

 

2 October 2025

 

 

Tavistock Reasserts Commitment to Shareholders in Titan Legal Dispute

 

 

Further to the disclosures made in the Company's financial statements for the year ended 31 March 2025, Tavistock today provides an update on the ongoing litigation with Titan Wealth Services Limited and Titan Asset Management Limited ("Titan").

 

In June 2021, Tavistock announced its entry into a 10-year strategic partnership with Titan Wealth Services Limited. As a part of the arrangements Titan acquired Tavistock's asset management business and range of risk rated UCITS sub-funds, branded ACUMEN. It was also offered the opportunity to acquire Tavistock's Model Portfolio Service ("MPS") but declined to do so.

 

Less than one year into the partnership, Tavistock began to uncover multiple breaches by Titan of the strategic partnership agreement and earnout arrangements. In the opinion of Tavistock's Board, Titan's failure to honour the undertakings that it gave regarding the management of the acquired business led to a collapse in the performance of the ACUMEN Funds.

 

In order to protect the interests of the Company's shareholders, in 2024, Tavistock put Titan on notice of its intention to issue legal proceedings seeking damages. In response Titan, issued a claim in the High Court against the Company on a peremptory basis. Tavistock refuted this claim in the strongest terms and issued its own counterclaim seeking damages for multiple breaches of contract, including failures relating to the management of the ACUMEN fund range and the misuse of confidential information.

 

In June 2025 Tavistock made an application to expand the scope of its counterclaim against Titan to include new causes of action in respect of Titan's MPS for breach of confidence, alleged misuse of trade secrets and copyright infringement, and to add Titan Wealth Holdings Limited as an additional party. 

 

Titan opposes the expansion of the scope of Tavistock's counterclaim and has applied at the same time to strike out parts of the counterclaims.

 

A Court hearing has now been listed for December 2025 to determine both parties' applications. The Board remains confident in the strength of its case and continues to defend Titan's claim and pursue its own counterclaims vigorously.

 

Tavistock has offered Titan the opportunity to resolve the dispute via mediation. To date, this offer has been rejected. Unless Titan's approach changes, Tavistock will continue to pursue its claims through the courts.

 

Brian Raven, Tavistock's Chief Executive, commented:

 

"This litigation is not just about damages - it is about accountability. The evidence is clear that Titan's conduct caused reputational and financial harm, and we will not allow our shareholders to bear the cost of its mismanagement."

 

ACUMEN Fund Performance Under Titan's Management

 

Between 27 August 2022 and 4 January 2024 (after Tavistock began to uncover multiple breaches of contract), while under Titan's management, the ACUMEN fund suite experienced a dramatic collapse in performance. In all cases, the funds ranked in the bottom quartile of their respective peer groups for that 16-month period, in the 99th or 100th percentile.

 

 

 

  

Performance post Titan's breaches of contract

(27th Aug 2022 - 4th Jan 2024)

Performance vs Benchmark

Quartile Rank

Fund Rank

Percentile Rank

ACUMEN Portfolio 4

-7.89%

4th

176/177

100th

ACUMEN Portfolio 5

-8.27%

4th

177/177

100th

ACUMEN Portfolio 6

-9.72%

4th

212/215

99th

ACUMEN Portfolio 7

-11.19%

4th

214/215

100th

ACUMEN Portfolio 8

-13.51%

4th

157/159

99th

Average

-10.12%

4th

100th

Source of data: FE Analytics

 

The Company continues to manage the litigation process efficiently and separately from its operational and strategic priorities, which remain unaffected. Adverse costs insurance is also in place.

 

ENDS

 

 

For further information:

 

Tavistock Investments Plc

Oliver Cooke

Brian Raven

 

Tel: 01753 867000

Allenby Capital Limited

(Nominated adviser and broker)

Corporate Finance:

Nick Naylor, Daniel Dearden-Williams

Sales and Corporate Broking:

Tony Quirke

 

 

Tel: 020 3328 5656

Flagstaff Communications

(Financial PR/IR)

Tim Thompson

Alison Allfrey

Anna Probert

tavistock@flagstaffcomms.com

Tel: 0207 129 1474

 

Infinite

(Litigation PR)

Ryan McSharry

Matthew Gilleard

 

 

Tel: 0207 269 1430

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUPGGAUUPAGWG
Date   Source Headline
8th Oct 201512:30 pmRNSResult of AGM
28th Sep 20157:00 amRNSCollaboration with BlackRock
10th Sep 20159:31 amRNSPosting of Accounts and Notice of AGM
25th Aug 20157:00 amRNSFinal Results
6th May 20157:01 amRNSExpansion Continues with Regional Acquisition
1st Apr 20157:00 amRNSAcquisition
23rd Mar 20157:00 amRNSInterim Results
20th Feb 20157:00 amRNSPlacing of New Ordinary Shares
17th Feb 20158:00 amRNSHolding(s) in Company
17th Feb 20157:00 amRNSChange of Accounting Reference Date
16th Feb 20153:03 pmRNSHolding(s) in Company
12th Feb 20151:45 pmRNSSchedule 1 update - Tavistock Investments Plc
12th Feb 201512:09 pmRNSResult of Open Offer and General Meeting
19th Jan 20157:00 amRNSSchedule 1 - Tavistock Investments Plc
19th Jan 20157:00 amRNSAcquisition, Placing and Open Offer
13th Oct 201412:00 pmRNSGrant of Options
10th Oct 20147:00 amRNSTrading Update
29th Sep 20147:00 amRNSAppointment of Broker
5th Sep 20147:00 amRNSHalf Yearly Report
1st Sep 20147:05 amRNSTavistock and Novia Announce Strategic Initiative
1st Sep 20147:00 amRNSEquity Fundraise and Convertible Loan Facility
28th Aug 20141:10 pmRNSResult of AGM
1st Aug 201411:33 amRNSNotice of AGM
13th Jun 20144:47 pmRNSHolding(s) in Company
4th Jun 20144:06 pmRNSHolding(s) in Company - Replacement
3rd Jun 20143:58 pmRNSHolding(s) in Company
30th May 201411:03 amRNSResult of General Meeting
16th May 201410:30 amRNSSchedule 1 - Tavistock Investments Plc
15th May 20147:00 amRNSAcquisitions and Placing
12th May 20147:00 amRNSFinal Results and Board Changes
23rd Jan 20148:49 amRNSHolding(s) in Company
9th Jan 20148:43 amRNSHolding(s) in Company
11th Dec 201310:28 amRNSHolding(s) in Company
4th Nov 20137:00 amRNSIssue of Equity
1st Nov 20134:32 pmRNSStmnt re Share Price Movement
17th Oct 20137:00 amRNSDirector/PDMR Shareholding
30th Sep 201312:16 pmRNSHalf Yearly Report
26th Sep 20137:00 amRNSHolding(s) in Company
29th Jul 20132:30 pmRNSResult of General Meeting
15th Jul 20137:00 amRNSFundraising and change of activity
1st Jul 201311:49 amRNSResult of AGM
18th Jun 20137:00 amRNSIssue of Equity
7th Jun 201310:00 amRNSFinal Results
24th May 20137:00 amRNSAppointment of Joint Broker
3rd May 20137:00 amRNSDirectorate Change
17th Apr 201311:00 amRNSChange of Adviser
28th Nov 20121:07 pmRNSSIPP Announcement
20th Nov 20121:16 pmRNSSIPP Announcement
9th Nov 20126:21 pmRNSHolding(s) in Company
14th Sep 20129:39 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.